English

Artiva Biotherapeutics, Inc.

EDGAR

ARTV Current report (8-K) · filed 2026-10-27

Annual consolidated revenue for 2025: about USD 0, using the latest reported figures. The previous period, 2024, was about USD 251K.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

0 USD

2024 Q4 · USD

Exact inputs and evidence

Revenue: 251000 USD Source
Revenue: 251000 USD Source

Operating cash flow

-14.7 million USD

2024 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -55032000 USD Source
Operating Cash Flow: -40382000 USD Source

Free cash flow

-14.7 million USD

2024 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -55032000 USD Source
Operating Cash Flow: -40382000 USD Source
Capital Expenditure: 642000 USD Source
Capital Expenditure: 578000 USD Source

Cash and cash equivalents: 301 million USD 2026-06-30 Source
Exact value

301454000 USD
Long-term debt including current maturities: Not available
Shares outstanding: Not available

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

251 thousand USD

2024-01-01 – 2024-12-31

Exact inputs and evidence

Revenue: 251000 USD · 2024-01-01 – 2024-03-31 Source
Revenue: 251000 USD · 2024-01-01 – 2024-06-30 Source
Revenue: 251000 USD · 2024-01-01 – 2024-03-31 Source
Revenue: 251000 USD · 2024-01-01 – 2024-09-30 Source
Revenue: 251000 USD · 2024-01-01 – 2024-06-30 Source
Revenue: 251000 USD · 2024-01-01 – 2024-12-31 Source
Revenue: 251000 USD · 2024-01-01 – 2024-09-30 Source

Net income

-90.8 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -21528000 USD · 2025-07-01 – 2025-09-30 Source
Net income: -83865000 USD · 2025-01-01 – 2025-12-31 Source
Net income: -63093000 USD · 2025-01-01 – 2025-09-30 Source
Net income: -23516000 USD · 2026-01-01 – 2026-03-31 Source
Net income: -25005000 USD · 2026-04-01 – 2026-06-30 Source

Operating cash flow

-75.3 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -62000000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -42824000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -76800000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -62000000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -21000000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -41300000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -21000000 USD · 2026-01-01 – 2026-03-31 Source

Capital expenditure

1.68 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Capital expenditure: 2166000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 1566000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 2587000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 2166000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 242000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 657000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 242000 USD · 2026-01-01 – 2026-03-31 Source

Free cash flow

-77 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -62000000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -42824000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -76800000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -62000000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -21000000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -41300000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -21000000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 2166000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 1566000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 2587000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 2166000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 242000 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 657000 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 242000 USD · 2026-01-01 – 2026-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-10-27.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 3 of 11 periods available· newest 2025-12-31
Operating income: 3 of 11 periods available· newest 2025-12-31
Net income: 3 of 11 periods available· newest 2025-12-31
Operating cash flow: 3 of 11 periods available· newest 2025-12-31
Capital expenditure: 3 of 11 periods available· newest 2025-12-31
Total assets: 3 of 11 periods available· newest 2025-12-31
Total liabilities: 3 of 11 periods available· newest 2025-12-31
Current assets: 3 of 11 periods available· newest 2025-12-31
Current liabilities: 3 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 3 of 11 periods available· newest 2025-12-31
long term debt: No compatible figures in this window
shares outstanding: No compatible figures in this window

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
-100%

Prior period

USD 251,000

2024-01-01 – 2024-12-31
Current period

USD 0

2025-01-01 – 2025-12-31

Exact inputs and evidence

0 − 251000 = -251000 USD

251000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
0 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Artiva Biotherapeutics, Inc. · 2025-12-31 Artiva Biotherapeutics, Inc. (edgar:1817241) Year-over-year change in Revenue: -251000 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-08T11:21:50Z Snapshot: 588e97eb496dc716ee92498375b529518547e90551cd113965c0d25807d7f4d3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1817241?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 0 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1817241/000119312526100135/artv-20251231.htm#4002452 Filing: 000119312526100135 Input fundies:Revenue: 251000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1817241/000119312526100135/artv-20251231.htm#4004074 Filing: 000119312526100135
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 18.49 million

Prior period

−USD 65.37 million

2024-01-01 – 2024-12-31
Current period

−USD 83.87 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-83865000 − -65373000 = -18492000 USD

-65373000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-83865000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Artiva Biotherapeutics, Inc. · 2025-12-31 Artiva Biotherapeutics, Inc. (edgar:1817241) Year-over-year change in Net income: -18492000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-08T11:21:50Z Snapshot: 588e97eb496dc716ee92498375b529518547e90551cd113965c0d25807d7f4d3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1817241?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -83865000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1817241/000119312526100135/artv-20251231.htm#4028149 Filing: 000119312526100135 Input fundies:NetIncome: -65373000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1817241/000119312526100135/artv-20251231.htm#4030006 Filing: 000119312526100135
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 21.77 million

Prior period

−USD 55.03 million

2024-01-01 – 2024-12-31
Current period

−USD 76.8 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-76800000 − -55032000 = -21768000 USD

-55032000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-76800000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Artiva Biotherapeutics, Inc. · 2025-12-31 Artiva Biotherapeutics, Inc. (edgar:1817241) Year-over-year change in Operating cash flow: -21768000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-08T11:21:50Z Snapshot: 588e97eb496dc716ee92498375b529518547e90551cd113965c0d25807d7f4d3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1817241?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -76800000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1817241/000119312526100135/artv-20251231.htm#2926897 Filing: 000119312526100135 Input fundies:OperatingCashFlow: -55032000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1817241/000119312526100135/artv-20251231.htm#2807328 Filing: 000119312526100135
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+303%

Prior period

USD 642,000

2024-01-01 – 2024-12-31
Current period

USD 2.59 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

2587000 − 642000 = 1945000 USD

642000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
2587000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Artiva Biotherapeutics, Inc. · 2025-12-31 Artiva Biotherapeutics, Inc. (edgar:1817241) Year-over-year change in Capital expenditure: 1945000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-08T11:21:50Z Snapshot: 588e97eb496dc716ee92498375b529518547e90551cd113965c0d25807d7f4d3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1817241?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 2587000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1817241/000119312526100135/artv-20251231.htm#2812139 Filing: 000119312526100135 Input fundies:CapitalExpenditure: 642000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1817241/000119312526100135/artv-20251231.htm#2813915 Filing: 000119312526100135
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 0
Operating costs Derived USD 89.81 million
Operating income −USD 89.81 million
Tax, interest and other Derived −USD 5.95 million
Net income −USD 83.87 million

Cash

Operating cash flow −USD 76.8 million
Capital expenditure USD 2.59 million
Free cash flow Derived −USD 79.39 million

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2023 Operating loss: operating costs were 192% of revenue.
2024 Operating loss: operating costs were 26,906% of revenue.
2025 Not shown: operating income or net income is not reported.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2023 2023-01-01 – 2023-12-31	33492000	64163000 Derived	-30671000	-1951000 Derived	-28720000	-50688000 Derived	Source 2023-01-01 – 2023-12-31: 33492000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -30671000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -28720000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -47430000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 3258000 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	251000	67533000 Derived	-67282000	-1909000 Derived	-65373000	-55674000 Derived	Source 2024-01-01 – 2024-12-31: 251000 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -67282000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -65373000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -55032000 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 642000 USD Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	0	89810000 Derived	-89810000	-5945000 Derived	-83865000	-79387000 Derived	Source 2025-01-01 – 2025-12-31: 0 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -89810000 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -83865000 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: -76800000 USD Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 2587000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 0 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20232023-12-31	Revenue	33492000	Revenue: 33492000 Open source
20242024-12-31	Revenue	251000	Revenue: 251000 Open source
20252025-12-31	Revenue	0	Revenue: 0 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-100% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20232023-12-31	Year over year	No prior comparable period	Revenue: 33492000 Open source
20242024-12-31	Year over year	-99.3%	Revenue: 251000 Open source Revenue: 33492000 Open source
20252025-12-31	Year over year	-100%	Revenue: 0 Open source Revenue: 251000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -26,805.6% 2024

Net margin -26,045% 2024

Free cash flow margin -22,180.9% 2024

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20232023-12-31	Operating margin	-91.6%	Operating Income: -30671000 Open source Revenue: 33492000 Open source
20242024-12-31	Operating margin	-26,805.6%	Operating Income: -67282000 Open source Revenue: 251000 Open source
20252025-12-31	Operating margin	Not reported	Operating Income: -89810000 Open source Revenue: 0 Open source
20232023-12-31	Net margin	-85.8%	Net Income: -28720000 Open source Revenue: 33492000 Open source
20242024-12-31	Net margin	-26,045%	Net Income: -65373000 Open source Revenue: 251000 Open source
20252025-12-31	Net margin	Not reported	Net Income: -83865000 Open source Revenue: 0 Open source
20232023-12-31	Free cash flow margin	-151.3%	Revenue: 33492000 Open source Operating Cash Flow: -47430000 Open source Capital Expenditure: 3258000 Open source
20242024-12-31	Free cash flow margin	-22,180.9%	Revenue: 251000 Open source Operating Cash Flow: -55032000 Open source Capital Expenditure: 642000 Open source
20252025-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -76800000 Open source Capital Expenditure: 2587000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -76.8M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20232023-12-31	Operating cash flow	-47430000	Operating Cash Flow: -47430000 Open source
20242024-12-31	Operating cash flow	-55032000	Operating Cash Flow: -55032000 Open source
20252025-12-31	Operating cash flow	-76800000	Operating Cash Flow: -76800000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -79.4M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20232023-12-31	Free cash flow	-50688000	Operating Cash Flow: -47430000 Open source Capital Expenditure: 3258000 Open source
20242024-12-31	Free cash flow	-55674000	Operating Cash Flow: -55032000 Open source Capital Expenditure: 642000 Open source
20252025-12-31	Free cash flow	-79387000	Operating Cash Flow: -76800000 Open source Capital Expenditure: 2587000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

16% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20232023-12-31	Liabilities / assets	48.2%	Total Liabilities: 50716000 Open source Total Assets: 105114000 Open source
20242024-12-31	Liabilities / assets	10.9%	Total Liabilities: 22940000 Open source Total Assets: 209581000 Open source
20252025-12-31	Liabilities / assets	16%	Total Liabilities: 20970000 Open source Total Assets: 130940000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

8.61× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20232023-12-31	Current assets / current liabilities	6.53×	Current Assets: 79821000 Open source Current Liabilities: 12227000 Open source
20242024-12-31	Current assets / current liabilities	15.39×	Current Assets: 188631000 Open source Current Liabilities: 12253000 Open source
20252025-12-31	Current assets / current liabilities	8.61×	Current Assets: 112666000 Open source Current Liabilities: 13087000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2023 2023-01-01 – 2023-12-31	−USD 28.72 million Exact value Exact value: -28720000 USD 2023-01-01 – 2023-12-31: -28720000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Artiva Biotherapeutics, Inc. · 2023-12-31 Artiva Biotherapeutics, Inc. (edgar:1817241) Net Income: -28720000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-08T11:21:50Z Snapshot: 588e97eb496dc716ee92498375b529518547e90551cd113965c0d25807d7f4d3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1817241/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -28720000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1817241/000095017025043837/artv-20241231.htm#3926309 Filing: 000095017025043837 The citation records this snapshot. The page link may show a newer release later.	−USD 47.43 million Exact value Exact value: -47430000 USD 2023-01-01 – 2023-12-31: -47430000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Artiva Biotherapeutics, Inc. · 2023-12-31 Artiva Biotherapeutics, Inc. (edgar:1817241) Operating Cash Flow: -47430000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-08T11:21:50Z Snapshot: 588e97eb496dc716ee92498375b529518547e90551cd113965c0d25807d7f4d3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1817241/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -47430000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1817241/000095017025043837/artv-20241231.htm#2751996 Filing: 000095017025043837 The citation records this snapshot. The page link may show a newer release later.	USD 3.26 million Exact value Exact value: 3258000 USD 2023-01-01 – 2023-12-31: 3258000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Artiva Biotherapeutics, Inc. · 2023-12-31 Artiva Biotherapeutics, Inc. (edgar:1817241) Capital Expenditure: 3258000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-08T11:21:50Z Snapshot: 588e97eb496dc716ee92498375b529518547e90551cd113965c0d25807d7f4d3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1817241/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3258000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1817241/000095017025043837/artv-20241231.htm#2758129 Filing: 000095017025043837 The citation records this snapshot. The page link may show a newer release later.	−USD 50.69 million Calculation and evidence -47430000 − 3258000 USD Exact free cash flow: -50688000 USD 2023-01-01 – 2023-12-31: -47430000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 3258000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Artiva Biotherapeutics, Inc. · 2023-12-31 Artiva Biotherapeutics, Inc. (edgar:1817241) Free cash flow: -50688000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-08T11:21:50Z Snapshot: 588e97eb496dc716ee92498375b529518547e90551cd113965c0d25807d7f4d3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1817241?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -47430000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1817241/000095017025043837/artv-20241231.htm#2751996 Filing: 000095017025043837 Input fundies:CapitalExpenditure: 3258000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1817241/000095017025043837/artv-20241231.htm#2758129 Filing: 000095017025043837 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 65.37 million Exact value Exact value: -65373000 USD 2024-01-01 – 2024-12-31: -65373000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Artiva Biotherapeutics, Inc. · 2024-12-31 Artiva Biotherapeutics, Inc. (edgar:1817241) Net Income: -65373000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-08T11:21:50Z Snapshot: 588e97eb496dc716ee92498375b529518547e90551cd113965c0d25807d7f4d3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1817241/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -65373000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1817241/000119312526100135/artv-20251231.htm#4030006 Filing: 000119312526100135 The citation records this snapshot. The page link may show a newer release later.	−USD 55.03 million Exact value Exact value: -55032000 USD 2024-01-01 – 2024-12-31: -55032000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Artiva Biotherapeutics, Inc. · 2024-12-31 Artiva Biotherapeutics, Inc. (edgar:1817241) Operating Cash Flow: -55032000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-08T11:21:50Z Snapshot: 588e97eb496dc716ee92498375b529518547e90551cd113965c0d25807d7f4d3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1817241/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -55032000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1817241/000119312526100135/artv-20251231.htm#2807328 Filing: 000119312526100135 The citation records this snapshot. The page link may show a newer release later.	USD 642,000 Exact value Exact value: 642000 USD 2024-01-01 – 2024-12-31: 642000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Artiva Biotherapeutics, Inc. · 2024-12-31 Artiva Biotherapeutics, Inc. (edgar:1817241) Capital Expenditure: 642000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-08T11:21:50Z Snapshot: 588e97eb496dc716ee92498375b529518547e90551cd113965c0d25807d7f4d3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1817241/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 642000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1817241/000119312526100135/artv-20251231.htm#2813915 Filing: 000119312526100135 The citation records this snapshot. The page link may show a newer release later.	−USD 55.67 million Calculation and evidence -55032000 − 642000 USD Exact free cash flow: -55674000 USD 2024-01-01 – 2024-12-31: -55032000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 642000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Artiva Biotherapeutics, Inc. · 2024-12-31 Artiva Biotherapeutics, Inc. (edgar:1817241) Free cash flow: -55674000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-08T11:21:50Z Snapshot: 588e97eb496dc716ee92498375b529518547e90551cd113965c0d25807d7f4d3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1817241?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -55032000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1817241/000119312526100135/artv-20251231.htm#2807328 Filing: 000119312526100135 Input fundies:CapitalExpenditure: 642000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1817241/000119312526100135/artv-20251231.htm#2813915 Filing: 000119312526100135 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 83.87 million Exact value Exact value: -83865000 USD 2025-01-01 – 2025-12-31: -83865000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Artiva Biotherapeutics, Inc. · 2025-12-31 Artiva Biotherapeutics, Inc. (edgar:1817241) Net Income: -83865000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-08T11:21:50Z Snapshot: 588e97eb496dc716ee92498375b529518547e90551cd113965c0d25807d7f4d3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1817241/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -83865000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1817241/000119312526100135/artv-20251231.htm#4028149 Filing: 000119312526100135 The citation records this snapshot. The page link may show a newer release later.	−USD 76.8 million Exact value Exact value: -76800000 USD 2025-01-01 – 2025-12-31: -76800000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Artiva Biotherapeutics, Inc. · 2025-12-31 Artiva Biotherapeutics, Inc. (edgar:1817241) Operating Cash Flow: -76800000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-08T11:21:50Z Snapshot: 588e97eb496dc716ee92498375b529518547e90551cd113965c0d25807d7f4d3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1817241/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -76800000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1817241/000119312526100135/artv-20251231.htm#2926897 Filing: 000119312526100135 The citation records this snapshot. The page link may show a newer release later.	USD 2.59 million Exact value Exact value: 2587000 USD 2025-01-01 – 2025-12-31: 2587000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Artiva Biotherapeutics, Inc. · 2025-12-31 Artiva Biotherapeutics, Inc. (edgar:1817241) Capital Expenditure: 2587000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-08T11:21:50Z Snapshot: 588e97eb496dc716ee92498375b529518547e90551cd113965c0d25807d7f4d3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1817241/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2587000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1817241/000119312526100135/artv-20251231.htm#2812139 Filing: 000119312526100135 The citation records this snapshot. The page link may show a newer release later.	−USD 79.39 million Calculation and evidence -76800000 − 2587000 USD Exact free cash flow: -79387000 USD 2025-01-01 – 2025-12-31: -76800000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 2587000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Artiva Biotherapeutics, Inc. · 2025-12-31 Artiva Biotherapeutics, Inc. (edgar:1817241) Free cash flow: -79387000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-08T11:21:50Z Snapshot: 588e97eb496dc716ee92498375b529518547e90551cd113965c0d25807d7f4d3 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1817241?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -76800000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1817241/000119312526100135/artv-20251231.htm#2926897 Filing: 000119312526100135 Input fundies:CapitalExpenditure: 2587000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1817241/000119312526100135/artv-20251231.htm#2812139 Filing: 000119312526100135 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

17 filings · 721 latest values · 721 originally reported values

Dataset published 2026-11-08. Source filing dates and reporting periods are shown separately.

Identifiers: 0001817241, 1817241, ARTV, edgar:1817241

Also known as Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics, Inc.

Latest quarter

Revenue

Operating cash flow

Free cash flow

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation